SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYNEXIS completes Phase 1 for SCY-247 and secures up to $214 million in BARDA funding.

What the company is saying

SCYNEXIS is highlighting the completion of Phase 1 studies for both intravenous and oral formulations of SCY-247, its second-generation antifungal candidate. The company frames this as a major milestone, emphasizing the potential for SCY-247 to address drug-resistant fungal infections and the flexibility offered by both IV and oral options. Todd Minga, M.D., SVP of Research and Development, is quoted to reinforce confidence in the clinical progress and the company's readiness to move to Phase 2, pending FDA agreement. The announcement places strong emphasis on the recently awarded BARDA contract, which could provide up to $214 million in non-dilutive funding if milestones are met, and describes the award as a cost-share arrangement. SCYNEXIS also reiterates its ability to fund near-term program costs within its current operating plan and maintains its previously communicated plans for SCY-770 and a projected cash runway into 2029. The tone is optimistic, focusing on regulatory designations and the potential impact of SCY-247, while providing only high-level financial context.

What the data suggests

The company enrolled 56 healthy participants in the Phase 1 IV study of SCY-247, with 42 receiving the drug and 14 on placebo, across seven cohorts. Dosing ranged up to 300 mg for single doses and up to 200 mg daily for seven days in multiple-dose cohorts. SCY-247 was generally well tolerated, with only mild to moderate infusion site reactions reported and no drug-related serious adverse events or discontinuations. IV doses of 50 mg or higher achieved exposures at or above the efficacy target (AUC 0–24 of 20 µg·h/mL) established in animal models, and oral doses of 100 mg or higher are also expected to reach this target based on prior studies. The BARDA contract is valued at up to $214 million, but is milestone-based and structured as a cost-share, so actual funding will depend on future progress. The company states it can cover its share of near-term costs from its current operating plan and projects a cash runway into 2029, but does not provide cash balances or burn rates. Regulatory designations (Orphan Drug, QIDP, Fast Track) have been granted for SCY-247, and the company plans to initiate a Phase 2 study next year, subject to FDA agreement. No efficacy data in patients or detailed pharmacokinetic results are disclosed.

Analysis

The announcement is upbeat, highlighting the completion of Phase 1 studies for both IV and oral SCY-247 and the award of a BARDA contract worth up to $214 million, contingent on milestone achievement. However, most of the key benefits—such as future funding, clinical efficacy in patients, and commercialisation—are forward-looking and dependent on successful progression through later-stage trials and regulatory milestones. The BARDA funding is not guaranteed but milestone-based, and the cost-share structure means SCYNEXIS must continue to fund a portion of development costs. No revenue, profit, or cash flow figures are disclosed, and the only financial reference is a projected cash runway into 2029, which is not substantiated with detailed data. The clinical results are limited to safety and pharmacokinetic targets, with efficacy only referenced via preclinical models. Thus, while the tone is positive and the progress is real for an early-stage biotech, the gap between narrative and realised value is moderate, with long timelines and significant capital requirements ahead.

Risk flags

• ●BARDA funding is milestone-based and not guaranteed; failure to achieve clinical or regulatory milestones could result in less than the full $214 million being received, limiting the company's ability to fund later-stage development.
• ●The cost-share structure requires SCYNEXIS to fund a portion of development costs; if expenses rise or timelines slip, the company may need additional capital beyond its current operating plan and projected cash runway.
• ●No efficacy data in patients has been disclosed; while safety and pharmacokinetic targets were met, clinical benefit in the target population remains unproven and is a key risk for future trial phases.
• ●Initiation of Phase 2 is subject to FDA agreement; regulatory delays or requests for additional data could push timelines out and increase costs.

Bottom line

SCYNEXIS has completed Phase 1 trials for both IV and oral SCY-247, showing good safety and pharmacokinetic results, and secured a BARDA contract worth up to $214 million if milestones are met. The company is positioned to start Phase 2 in 2027, but actual funding and future progress depend on meeting clinical and regulatory milestones. The announcement demonstrates real clinical progress and a strong potential funding source, but lacks patient efficacy data and detailed financials. Investors should focus on the execution of Phase 2, the pace of BARDA milestone achievement, and any updates on cash usage or additional funding needs. The most important takeaway is that while the headline BARDA figure is large, its realization is tied to future success in clinical development.

Announcement summary

(NASDAQ: SCYX) SCYNEXIS, Inc. announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, a second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is being developed in both oral and IV formulations for the treatment and prevention of invasive fungal infections, with activity against drug-resistant fungi. Todd Minga, M.D., SVP of Research and Development at SCYNEXIS, stated that with Phase 1 studies of both formulations now complete, the company can refine plans for the next stage of development. SCYNEXIS was recently awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding, if milestones are achieved, to advance SCY-247 development. The BARDA award is structured as a cost-share arrangement, with BARDA supporting eligible SCY-247 costs, and SCYNEXIS expects to fund its share of near-term program costs within its existing operating plan. The company’s previously communicated development plans for SCY-770, including initiation of a Phase 2 study in the fourth quarter of 2026 and a projected cash runway into 2029, remain unchanged. The Phase 1 study enrolled 56 healthy participants across seven cohorts: 42 received SCY-247 by peripheral IV infusion and 14 received placebo. Single ascending doses up to 300 mg and multiple ascending doses once daily for seven days up to 200 mg were evaluated. SCY-247 administered by peripheral IV infusion was generally well tolerated, with the most common adverse reactions being mild to moderate erythema and pain at the infusion site. There were no drug-related serious adverse events or discontinuations due to a related adverse event. IV doses of 50 mg once daily or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis (AUC 0–24 of 20 µg·h/mL). A previously completed Phase 1 study indicated that oral doses of 100 mg or higher are also anticipated to achieve the target exposure for efficacy. SCY-247 has demonstrated in vitro and in vivo activity against several challenging Candida strains, including Candida auris and most azole- and echinocandin-resistant strains. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP), and Fast Track designations by the U.S. Food and Drug Administration. Future activities for this project may be funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), and BARDA under contract number 75A50126C00007. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform includes BREXAFEMME® (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, currently in clinical development for invasive fungal diseases.

Disagree with this article?